Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

2 FTSE 100 growth giants that could fund your retirement

These two rising FTSE 100 (INDEXFTSE:UKX) stocks could help you to a comfortable old age.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

If you’re investing for your retirement, what should you do differently? I’d say nothing at all, because a good retirement investment strategy is simply a good investment strategy.Strategies aimed at maximising your long-term returns have a habit of turning out to be the most successful, whatever your age or plans.

To that end, there are many good stocks that should be good for long-term growth, and today I’m looking at two from the FTSE 100.

A new growth phase

AstraZeneca (LSE: AZN) has suffered a bit in recent years as the loss of patent protection on some key drugs has opened the way for cheap generic competition. Earnings have fallen as a result and the company has been working hard to focus on its core business and reinvigorate its development pipeline. 

You might imagine that the shares have had a few tough years as we await news of a return to earnings growth. But you’d be wrong, as AstraZeneca shares have actually gained 65% over the past five years, to 4,725p today. And over that period, the company has kept on paying dividends of around 5% and better.

So how will AstraZeneca do in a renewed period of sustainable growth? I think it will do very well indeed, and that were are on the verge of exactly that. Analysts seem to think the turnaround in earnings per share should happen in 2018 as the changes made by Pascal Soriot since he took the helm in 2012 are bearing fruit.

As of 2016 results time, 12 new drugs candidates had reached the Phase III stage or were under regulatory review, targeting oncology, cardiovascular and metabolic diseases and respiratory conditions, which are all growing first-world problems. And there are some clear candidates to become the blockbusters of tomorrow.

AstraZeneca shares are on a P/E of 15 on 2018 forecasts, and I reckon that could shrink rapidly over the next 10 years and make the shares look a real bargain today.

A hidden secret

GKN (LSE: GKN) is a company that has largely evaded me so far as its share price has somewhat stagnated in recent years, but while searching for solid growth candidates it has caught my eye. There was a minor dip in 2015, but since the end of 2012 the automotive engineer has grown its earnings per share by 18% — and forecasts suggest a gain of 37% by 2018.

Over the same period, dividends have been modest in the 2%-3% range, but they’re progressive and have been growing well ahead of inflation. That trend is expected to continue, and for me a dividend that is growing reliably in real terms is a very desirable thing.

Results for 2016 showed a 22% rise in revenue, which boosted adjusted pre-tax profit by 12%, and forecasts suggest two more years of earnings growth. And despite a one-off restructuring charge of £39m, the firm reckoned that has resulted in annualised savings of £30m.

We’re looking at a company here that has come through a restructuring phase, has what I see as attractive growth potential over the next decade and more, and whose shares are trading on a forward P/E of only around 10. That looks to me to be a great candidate for a retirement portfolio.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK owns shares of GKN. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Two female adult friends walking through the city streets at Christmas. They are talking and smiling as they do some Christmas shopping.
Investing Articles

2 British income shares to consider before the Christmas boom

Our writer scoured historical market data to uncover which income shares typically do well in the run up to Christmas.…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Will Rolls-Royce shares continue their epic run into 2026 and beyond?

Noting that differences of opinion make the world go round, James Beard discusses what might happen to Rolls-Royce’s shares next…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

I asked ChatGPT if I’ve left it too late to buy Lloyds shares. Here’s what it said…

James Beard turns to artificial intelligence in an attempt to assess whether there’s any value left in Lloyds Banking Group…

Read more »

Man thinking about artificial intelligence investing algorithms
Investing Articles

7 moves I’ve just made in my Stocks and Shares ISA

I've been harvesting some gains recently in my Stocks and Shares ISA. Here are the four names I've been buying…

Read more »

Tabletop model of a bear sat on desk in front of monitors showing stock charts
Investing Articles

How on earth is this FTSE 100 stock up 319% in 2025?

It's been a barnstormer of a year for FTSE 100 stocks, but one unheralded mining firm is massively outperforming the…

Read more »

Night Takeoff Of The American Space Shuttle
Investing Articles

Will the Rolls-Royce share price double in 2026?

The Rolls-Royce share price remains one of the FTSE 100's best performers. Royston Wild asks if the engineer can do…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

Could ‘Drastic Dave’ save the Diageo share price in 2026?

Diageo will get a new boss on 1 January. But will the appointment of Sir Dave Lewis help reverse the…

Read more »

Investing Articles

The biggest ‘no-brainer’ stock in my ISA and SIPP as we approach 2026 is…

Edward Sheldon owns a lot of high-quality stocks within his ISA and pension. But this one – a household name…

Read more »